Recent advances in natriuretic peptides in congestive heart failure

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 643-652

  Boerrigter, Guido ^a   Burnett Jr , John C ^a  

^a Mayo Clinic   (United States)

Author keywords

Cyclic guanosine monophosphate; Heart failure; Natriuretic peptides; Nesiritide; Neurohumoral activation

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; ENDOTHELIN 1; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NESIRITIDE; OMAPATRILAT; UNCLASSIFIED DRUG; URODILATIN; VASOPEPTIDASE INHIBITOR;

ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART STROKE VOLUME; HUMAN; KIDNEY FUNCTION; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; REVIEW; SIDE EFFECT; SODIUM EXCRETION; VASODILATATION;

ATRIAL NATRIURETIC FACTOR; ENZYME ACTIVATION; GUANYLATE CYCLASE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; MYOCARDIUM; NATRIURESIS; NATRIURETIC PEPTIDE, BRAIN;

EID: 3042847645     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.643     Document Type: Review

References (58)

1. McDONAGH TA, MORRISON CE, LAWRENCE A et al.: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 350(9081):829-833.
2. HOBBS RE, MILLS RM, YOUNG JB: An update on nesiritide for treatment of decompensated heart failure. Expert Opin. Investig. Drugs (2001) 10(5):935-942.
3. CHEN HH, BURNETT JC: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc. Assoc. Am. Physicians (1999) 111(5):406-416.
4. YAMAMOTO K, BURNETT JC Jr, REDFIELD MM: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am. J. Physiol (1997) 273(5 Pt. 2):H2406-H2414.
5. RODEN R, ASANO K, WICHMANN S et al.: Inotropic effect of human B-type natriuretic peptide in the failing human heart. J. Card. Fail. (1998) 4:19.
6. TAMURA N, OGAWA Y, CHUSHO H et al.: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA (2000) 97(8):4239-4244.
7. STEVENS TL, BURNETT JC Jr, KINOSHITA M, MATSUDA Y, REDFIELD MM: A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J. Clin. Invest. (1995) 95(3):1101-1108.
8. JEDLITSCHKY G, BURCHELL B, KEPPLER D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. (2000) 275(39):30069-30074.
9. RODEHEFFER RJ, NARUSE M, ATKINSON JB et al.: Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation (1993) 88(2):364-371.
10. NAKAGAWA O, OGAWA Y, ITOH H et al.: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J. Clin. Invest. (1995) 96(3):1280-1287.
11. PROTTER AA, WALLACE AM, FERRARIS VA, WEISHAAR RE: Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am. J. Hypertens. (1996) 9(5):432-436.
12. COLUCCI WS, ELKAYAM U, HORTON DP et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. (2000) 343(4):246-253.
13. BRUNNER-LA ROCCA HP, KAYE DM, WOODS RL, HASTINGS J, ESLER MD: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. (2001) 37(5):1221-1227.
14. ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. (1998) 4(1):37-44.
15. YASUE H, YOSHIMURA M: Natriuretic peptides in the treatment of heart failure. J. Card. Fail. (1996) 2(Suppl. 4):S277-S285.
16. ARONSON D, BURGER AJ: Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am. J. Cardiol. (2002) 90(4):435-438.
17. MICHAELS AD, KLEIN A, MADDEN JA, CHATTERJEE K: Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation (2003) 107(21):2697-2701.
18. YOSHIMURA M, YASUE H, MORITA E et al.: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 84(4):1581-1588.
19. YOSHIMURA M, YASUE H, OGAWA H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can. J. Physiol. Pharmacol. (2001) 79(8):730-735.
20. JENSEN KT, CARSTENS J, PEDERSEN EB: Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am. J. Physiol. (1998) 274(1 Pt. 2):F63-F72.
21. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATION IN THE MANAGEMENT OF ACUTE HEART CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J. Am. Med. Ass. (2002) 287(12):1531-1540.
22. BURGER AJ, HORTON DP, LEJEMTEL T et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. (2002) 144(6):1102-1108.
23. BOERRIGTER G, COSTELLO-BOERRIGTER LC, CATALIOTTI A et al.: Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation (2003) 107(5):686-689.
24. HILLEGE HL, GIRBES AR, DE KAM PJ et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation (2000) 102(2):203-210.
25. DRIES DL, EXNER DV, DOMANSKI MJ, GREENBERG B, STEVENSON LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. (2000) 35(3):681-689.
26. KRUMHOLZ HM, CHEN YT, VACCARINO V et al.: Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. Am. J. Cardiol. (2000) 85(9):1110-1113.
27. SCHRIER RW, ABRAHAM WT: Hormones and hemodynamics in heart failure. N. Engl. J. Med. (1999) 341(8):577-585.
28. VAN DER ZK, HOUBEN AJ, HOFSTRA L, KROON AA, DE LEEUW PW: Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am. J. Physiol. Heart Circ. Physiol. (2003) 285(3):H1206-H1212.
29. MARCUS LS, HART D, PACKER M et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 94(12):3184-3189.
30. AKABANE S, MATSUSHIMA Y, MATSUO H et al.: Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur. J. Pharmacol. (1991) 198(2-3):143-148.
31. GOTTLIEB SS, BRATER DC, THOMAS I et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105(11):1348-1353.
32. CODY RJ, KUBO SH, PICKWORTH KK: Diuretic treatment for the sodium retention of congestive heart failure. Arch. Intern. Med. (1994) 154(17):1905-1914.
33. BAYLISS J, NORELL M, CANEPA-ANSON R, SUTTON G, POOLE-WILSON P: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart J. (1987) 57(1):17-22.
34. CATALIOTTI A, BOERRIGTER G, COSTELLO-BOERRIGTER LC et al.: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 109:1680-1685.
35. KISHIMOTO I, HAMRA FK, GARBERS DL: Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. Can. J. Physiol. Pharmacol. (2001) 79(8):715-722.
36. ELLMERS LJ, KNOWLES JW, KIM HS et al.: Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. (2002) 283(2):H707-H714.
37. TSURUDA T, BOERRIGTER G, HUNTLEY BK et al.: Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. (2002) 91(12):1127-1134.
38. KAPOUN AM, LIANG F, O'YOUNG G et al.: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-{β} in primary human cardiac fibroblasts. Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. (2004)
39. HAYASHI M, TSUTAMOTO T, WADA A et al.: Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J. Am. Coll. Cardiol. (2001) 37(7):1820-1826.
40. KONSTAM MA, ROUSSEAU MF, KRONENBERG MW et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation (1992) 86(2):431-438.
41. KONSTAM MA, KRONENBERG MW, ROUSSEAU MF et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation (1993) 88(5 Pt. 1):2277-2283.
42. GROENNING BA, NILSSON JC, SONDERGAARD L et al.: Antiremodelling effects on the left ventricle during β-blockade with metoprolol in the treatment of chronic heart failure. J. Am. Coll. Cardiol. (2000) 36(7):2072-2080.
43. DOUGHTY RN, WHALLEY GA, GAMBLE G, MacMAHON S, SHARPE N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J. Am. Coll. Cardiol. (1997) 29 (5):1060-1066.
44. NORTHRIDGE DB, CURRIE PF, NEWBY DE et al.: Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur. J. Heart Fail. (1999) 1(1):67-72.
45. CLELAND JG, SWEDBERG K: Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (1998) 351(9116):1657-1658.
46. ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356(9230):615-620.
47. CHEN HH, GRANTHAM JA, SCHIRGER JA et al.: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J. Am. Coll. Cardiol. (2000) 36(5):1706-1712.
48. CHEN HH, REDFIELD MM, SCHIRGER JA, CATALIOTTI A, BURNETT JC: Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J. Card. Fail. (2004) 10(2):115-119.
49. CHEN HH, LAINCHBURY JG, HARTY GJ, BURNETT JC, JR.: Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation (2002) 105(8):999-1003.
50. YANCY C, SALTZBERG M, BERKOWITZ R, HORTON D, SILVER M: Management of patients with chronic decompensated heart failure: results from the follow-up serial infusions of nesiritide (FUSION) trial. Circulation (2003) 108(17):IV-694:3156.
51. LISY O, JOUGASAKI M, HEUBLEIN DM et al.: Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. (1999) 56(2):502-508.
52. LISY O, LAINCHBURY JG, LESKINEN H, BURNETT JC Jr: Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. hypertension (2001) 37(4):1089-1094.
53. CHEN HH, LAINCHBURY JG, BURNETT JC Jr: Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J. Am. Coll. Cardiol. (2002) 40(6):1186-1191.
54. FORSSMANN W, MEYER M, FORSSMANN K: The renal urodilatin system: clinical implications. Cardiovasc. Res. (2001) 51(3):450-462.
55. STASCH JP, BECKER EM, ALONSO-ALIJA C et al.: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410(6825):212-215.
56. STASCH JP, SCHMIDT P, ALONSO-ALIJA C et al.: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. (2002) 136(5):773-783.
57. BOERRIGTER G, COSTELLO-BOERRIGTER LC, CATALIOTTI A et al.: Cardiorenal and humoral actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure. Circulation (2003) 108(17):IV-398:1840.
58. HILLEMAN D, LENZ T, MALESKER M, FORAL P, HUNTER C: Pharmacoeconomic analysis of nesiritide in decompensated heart failure: a multi-center study. Circulation (2003) 108(17):IV-556:2535.